CureVac stock gains as COVID vaccine candidates show promise
CureVac N.V. shares (CVAC) gained 3% premarket on Friday as the company released new data from a trial of its mRNA COVID-19 vaccine candidates, which it is developing in collaboration with GSK PLC (GSK). An investigational monovalent shot as well as a bivalent vaccine candidate successfully boosted antibody levels and were generally well tolerated across dosages, CureVac said in a release. All three dose levels tested were below those used in mRNA-based COVID vaccines currently licensed in the U.S. and European Union, the company said. CureVac said it is in "advanced discussions" with regulators to chart a path for a phase 3 study of the vaccine candidates. If approved, the shots would compete with mRNA Covid vaccines already available from Moderna Inc. (MRNA) and Pfizer Inc. (PFE). CureVac shares are down 34% over the past 12 months, while the S&P 500 has gained 23%. GSK's American depositary receipts fell 0.5% premarket on Friday and have gained 13.3% over the past 12 months.
-Eleanor Laise
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
01-05-24 0759ET
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s Happening in the Markets This Week
-
Worst-Performing Stock ETFs of the Quarter
-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Consumer Defensives: Despite Angst, Thirsty Investors Have Names to Pursue
-
Industrials: Many Stocks Overvalued After Q3 Outperformance
-
Basic Materials: Despite Index Rise, We See Multiple Long-Term Opportunities
-
What the Election Could Mean for Big Tech Stocks
-
3 Lessons From Recent Stock Market Drama
-
Consumer Cyclicals: Even Amid Moderating Consumer Spending, We See Discounts
-
Healthcare: Valuations Look Fair Overall, With Select Industries Still Undervalued
-
Utilities: Falling Interest Rates, Growth Outlook Boosting Stocks